Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integration
Immune checkpoint blockade improves outcomes in defined settings of triple-negative breast cancer (TNBC), but treatment failure does not identify a single biological mechanism or an interchangeable set of remedies. This focused narrative review examine…